Distant metastasis-free survival (DMFS) may be affected by clinicopathological factors, including lymphovascular invasion (LVI), Ki-67 expression, human epidermal growth factor receptor 2 (HER-2) status, estrogen (ER) or progesterone (PR) status, lymph node stage, and tumor size. Here, ERBB2 is linked to neoplasm.